• Overview
  • Eligibility
  • More info
  • Locations

Clinical Evaluation of the Tolerability of Using a Post Treatment Topical Adjuvant Combination Following Fractional Radiofrequency Ablation Using the Venus Viva (NCT02896569)

The purpose of this study is to compare the tolerability of the application of a combination of a serum containing human bone marrow stem cell derived growth factor (SCR Complex) and cytokines and a botanical lipid-based occlusive (Bio Cel) immediately following fractional radiofrequency treatment using the Venus Viva versus standard of care.
  • Other: Topical combination therapy
    • SCR Complex
    • Bio Cel
Ages eligible for Study
21 Years to 60 Years
Genders eligible for Study
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Inclusion Criteria:
  • Undergoing a dermatological procedure requiring ablation and resurfacing of the facial skin utilizing the Venus Viva™ SR system.
  • Women of child-bearing age are required to be using a reliable method of birth control prior to enrollment and throughout their participation in the study.
  • Able to tolerate the treatment as determined by a test spot application(s).
Exclusion Criteria:
  • Superficial metal or other implants in the treatment area
  • Tattoos, permanent makeup, scars or piercings in the treatment area.
  • Any active condition in the treatment area, such as sores, psoriasis, eczema and rash.
  • Any surgical procedure in the treatment area within the last three months or before complete healing.
  • Receiving therapies or medication that may interfere with the study treatment.
Randomized, open-label, multi-centre study to evaluate the tolerability of the application of a combination of a serum containing human bone marrow stem cell derived growth factor and cytokines (SCR Complex™) and a botanical lipid based occlusive (Bio Cel™) following facial fractional RF treatments using the Venus Viva™ SR system. Each subject will receive 2 treatments separated by a 3-week interval. Subjects will complete a VAS and Tolerability Scale immediately following each treatment. Telephone follow-up calls by the site will ask the subject to respond to the Self-Report Adverse Event Questionnaire 24 and 72 hours after the first treatment and 24 hours after the second treatment. Subjects will complete a Home Tolerability Scale 24 and 72 hours after the first treatment and 24 hours after the second treatment. Subjects will return for the final FU visit and be asked to respond to the Self-Report Adverse Event Questionnaire and complete the Home Tolerability Scale for 72 hours. The investigator will also evaluate the subject's improvement using the GAIS at this visit.

1 locations

United States (1)
  • Dr. George Taylor
    Not specified
    Newport Beach, California, United States, 92660
Status:
completed
Type:
Interventional
Phase:
-
Start:
31 July, 2016
Updated:
26 March, 2017
Participants:
51
A girl giving information about available additional trials.

FindMeCure helps you find, understand and join clinical trials from all over the world.

There are more clinical trials for your condition!